Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck & Co.
Pharma
Merck’s Lynparza-Keytruda plan sputters in 2nd lung cancer trial
The two flops in metastatic NSCLC, and a separate AstraZeneca setback, don't bode well for Merck's remaining Keytruda-Lynparza study in stage 3 tumors.
Angus Liu
Mar 21, 2024 10:28am
IFF is selling off its pharma solutions business for $2.85B
Mar 19, 2024 10:40am
Merck claims digital crown, holding off challenge from AZ, BMS
Mar 15, 2024 10:30am
Drugmakers counter HHS' first offers in Medicare price talks
Mar 4, 2024 4:09pm
Moderna's COVID manufacturing cuts lead to layoffs
Mar 1, 2024 12:13pm
NY attorney general wants FDA to tweak Singulair's safety label
Feb 27, 2024 9:25am